Incyte Stock Forecast, Price & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INCY shares have increased by 18.8% and is now trading at $85.42.
View which stocks have been most impacted by COVID-19.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Incyte or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Incyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Incyte is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.46 by $0.23. The biopharmaceutical company earned $620.64 million during the quarter, compared to analyst estimates of $622.48 million. Incyte had a negative return on equity of 13.66% and a negative net margin of 13.62%. The business's revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.82 earnings per share.
View Incyte's earnings history.

23 brokers have issued 1-year target prices for Incyte's shares. Their forecasts range from $86.00 to $124.00. On average, they expect Incyte's stock price to reach $102.95 in the next year. This suggests a possible upside of 20.5% from the stock's current price.
View analysts' price targets for Incyte.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Kite Pharma (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.80%), State Street Corp (3.99%), UBS Asset Management Americas Inc. (1.05%), California Public Employees Retirement System (0.70%), The Manufacturers Life Insurance Company (0.62%) and First Trust Advisors LP (0.51%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, UBS Asset Management Americas Inc., AQR Capital Management LLC, Victory Capital Management Inc., Los Angeles Capital Management & Equity Research Inc., NN Investment Partners Holdings N.V., State of Alaska Department of Revenue, and WINTON GROUP Ltd. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte.

INCY stock was bought by a variety of institutional investors in the last quarter, including Jupiter Asset Management Ltd., Cambiar Investors LLC, Point72 Asset Management L.P., ARK Investment Management LLC, State Street Corp, TD Asset Management Inc., The Manufacturers Life Insurance Company, and Morgan Stanley.
View insider buying and selling activity for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $85.42.

Incyte has a market capitalization of $18.71 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]